Premium
Lyell Immunopharma Inc (LYEL)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early...
Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0284 | -4.65650106575 | 0.6099 | 0.6355 | 0.5545 | 796362 | 0.5974121 | CS |
| 4 | -0.0435 | -6.96 | 0.625 | 0.6522 | 0.5505 | 844839 | 0.59124681 | CS |
| 12 | -0.5185 | -47.1363636364 | 1.1 | 1.16 | 0.5505 | 1159783 | 0.76463219 | CS |
| 26 | -0.8385 | -59.0492957746 | 1.42 | 1.62 | 0.5505 | 1091612 | 0.99476266 | CS |
| 52 | -1.2085 | -67.5139664804 | 1.79 | 3.2556 | 0.5505 | 1012912 | 1.50414394 | CS |
| 156 | -5.0885 | -89.7442680776 | 5.67 | 8.74 | 0.5505 | 1053931 | 3.17913343 | CS |
| 260 | -18.1685 | -96.8986666667 | 18.75 | 19.84 | 0.5505 | 961336 | 4.00360975 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
